REGULATED INFORMATIONPRESS
RELEASE
Transparency notifications pursuant to Article
14 of the Law of May 2, 2007
Leuven (Belgium) - June 19, 2018, 22:00h
CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix")
announced today that it received transparency notifications
pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding
the publication of major holdings in issuers whose securities are
admitted to trading on a regulated market and including various
provisions.
Summary of the notifications
It concerns the following two notifications:
- On June 14, 2018, TiGenix received a joint transparency
notification from Takeda Pharmaceutical Company Limited and
Grifols, S.A. following the acquisition of voting securities or
voting rights and the termination of an agreement to act in concert
on June 8, 2018, after which Takeda Pharmaceutical Company Limited
(including through its subsidiary Takeda Pharmaceuticals
International AG) holds 268,309,029 voting rights in TiGenix
(90.62% of the total number of voting rights). As a result Takeda
Pharmaceutical Company Limited crossed the 90% threshold and
Grifols, S.A. downward crossed the lowest threshold (3%) of the
total voting rights of TiGenix.
- On June 18, 2018, TiGenix received a transparency notification
from Bank of America Corporation, following the disposal of
financial instruments that are treated as voting securities on June
11, 2018, after which Bank of America Corporation (through its
controlled entities Bank of America National Association and
Merrill Lynch Professional Clearing Corporation) downward crossed
the lowest threshold (3%) of the total voting rights of
TiGenix.
1. Content of the notification of Takeda
Pharmaceutical Company Limited and Grifols, S.A.
Date of the notification: June 11, 2018.
Reason of the notification: acquisition or
disposal of voting securities or voting rights / termination of an
agreement to act in concert.
Persons subject to the notification requirement:
Takeda Pharmaceutical Company Limited (with address at 1-1
Doshomachi 4-Chome, Chuo-ku, Osaka 540-8645, Japan), who is a
parent undertaking/controlling person and who is acting in concert
with Grifols S.A. (with address at Avenida de la Generalitat 152,
08147 Sant Cugat de Vallès, Barcelona, Spain), who is a parent
undertaking/controlling person.
Date on which the threshold was crossed: June 8,
2018.
Threshold that was crossed: 90% (Takeda
Pharmaceutical Company Limited); 3% (Grifols, S.A.).
Denominator: 296,067,856.
Details of the notification: following the
acquisition of voting securities or voting rights, the number of
voting rights was as follows:
- Takeda Pharmaceutical Company Limited held 256,657,251 voting
securities (86.69% of the total number of voting rights); and
- Takeda Pharmaceuticals International AG held 11,651,778 voting
securities (3.94% of the total number of voting rights);
subtotal: 268,309,029 voting rights (90.62% of the total number
of voting rights).
- Grifols S.A. held 0 voting securities;
- Gri-Cel S.A. held 0 voting securities, and
- Grifols Worldwide Operations Ltd. held 0 voting
securities.
Chain of controlled undertakings through which
the holdings are effectively held: 1. Takeda Pharmaceuticals
International AG is controlled by Takeda Pharma A/S, which is
controlled by Takeda A/S, which is controlled by Takeda
Pharmaceutical Company Limited and by Takeda Europe Holdings B.V.,
which is controlled by Takeda Pharmaceutical Company Limited. 2.
Gri-Cel, S.A. is controlled by Instituto Grifols, S.A., which is
controlled by Grifols, S.A. 3. Grifols Worldwide Operations Ltd. is
controlled by Grifols, S.A.
2. Content of the notification of Bank of
America Corporation
Date of the notification: June 18, 2018.
Reason of the notification: acquisition or
disposal of financial instruments that are treated as voting
securities / downward crossing of the lowest threshold.
Person subject to the notification requirement:
Bank of America Corporation (with address at Wilmington, D.E.,
United States), who is a parent undertaking/controlling person.
Date on which the threshold was crossed: June
11, 2018.
Threshold that was crossed: 3%.
Denominator: 296,067,856.
Details of the notification: following the
disposal of financial instruments that are treated as voting
securities, the number of voting rights was as follows:
- Bank of America Corporation held 0 voting securities; and
- Bank of America, National Association held 0 voting
securities;
and the number of equivalent financial instruments was as
follows:
- Merrill Lynch Professional Clearing Corporation held 0 voting
rights that may be acquired if the financial instruments (rights of
use) are exercised (0% of the total number of voting rights).
Chain of controlled undertakings through which
the holding is effectively held: Merrill Lynch Professional
Clearing Corporation and Bank of America, National Association are
controlled by Bank of America Corporation. Bank of America
Corporation is not a controlled entity.
This press release and the above-mentioned transparency
notifications can be consulted on our website:
- press release:
http://tigenix.com/news-media/press-releases
- notifications:
http://tigenix.com/investors/share-information/shareholder-overview
For more information:
TiGenixClaudia JiménezSenior Director Investor
Relations and CommunicationsTel: +34918049264
Claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and NASDAQ: TIG)
is an advanced biopharmaceutical company developing novel therapies
for serious medical conditions by exploiting the anti-inflammatory
properties of allogeneic, or donor-derived, stem cells.
TiGenix lead product, Alofisel
(darvadstrocel), previously Cx601, received European Commission
(EC) approval for the treatment of complex perianal fistulas in
adult patients with non-active/mildly active luminal Crohn's
disease, when fistulas have shown an inadequate response to at
least one conventional or biologic therapy. A global Phase III
trial intended to support a future U.S. Biologic License
Application (BLA) started in 2017. TiGenix has entered into a
licensing agreement with Takeda, a global pharmaceutical company
active in gastroenterology, under which Takeda acquired the
exclusive right to develop and commercialize Alofisel for complex
perianal fistulas outside the U.S. TiGenix' second adipose-derived
product, Cx611, is undergoing a Phase I/II trial in severe sepsis -
a major cause of mortality in the developed world. TiGenix is
headquartered in Leuven (Belgium) and has operations in Madrid
(Spain) and Cambridge, MA (USA). For more information, please visit
http://www.tigenix.com.
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jul 2023 to Jul 2024